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Abstract
Background: After a long and controversial debate methadone maintenance treatment (MMT) was first introduced in
Germany in 1987. The number of patients in MMT – first low because of strict admission criteria – increased considerably
since the 1990s up to some 65,000 at the end of 2006. In Germany each general practitioner (GP), who has completed
an additional training in addiction medicine, is allowed to prescribe substitution drugs to opioid dependent patients.
Currently 2,700 GPs prescribe substitution drugs. Psychosocial care should be made available to all MMT patients.
Results: The results of research studies and practical experiences clearly indicate that patients benefit substantially from
MMT with improvements in physical and psychological health. MMT proves successful in attaining high retention rates
(65 % to 85 % in the first years, up to 50 % after more than seven years) and plays a major role in accessing and maintaining
ongoing medical treatment for HIV and hepatitis. MMT is also seen as a vital factor in the process of social re-integration
and it contributes to the reduction of drug related harms such as mortality and morbidity and to the prevention of
infectious diseases. Some 10 % of MMT patients become drug-free in the long run. Methadone is the most commonly
prescribed substitution medication in Germany, although buprenorphine is attaining rising importance. Access to MMT
in rural areas is very patchy and still constitutes a problem. There are only few employment opportunities for patients
participating in MMT, although regular employment is considered unanimously as a positive factor of treatment success.
Substitution treatment in German prisons is heterogeneous in access and treatment modalities. Access is very patchy
and the number of inmates in treatment is limited. Nevertheless, substitution treatment plays a substantial part in the
health care system provided to drug users in Germany.
Conclusion: In Germany, a history of substitution treatment spanning 20 years has meanwhile accumulated a wealth of
experience, e.g. in the development of research on health care services, guidelines and the implementation of quality
assurance measures. Implementing substitution treatment with concomitant effects and treatment elements such as drug
history-taking, dosage setting, co-use of other psychoactive substances (alcohol, benzodiazepines, cocaine), management
of 'difficult patient populations', and integration into the social environment has been arranged successfully. Also
psychosocial counseling programmes adjuvant to substitution treatment have been established and, in the framework of
a pilot project on heroin-based treatment, standardised manuals were developed. Research on allocating opioid users to
the 'right' form of therapy at the 'right' point in time is still a challenge, though the pilot project 'heroin-based treatment'
brought experience with patients who do not benefit from methadone treatment. There is also expertise in the
treatment of specific co-morbidity such as HIV/AIDS, hepatitis and psychiatric disorders. The promotion and involvement
of self-help groups plays an important part in the process of successful substitution treatment.
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Historical background
Heroin found its way onto the German illicit market
around 1970 followed by a rapid increase in the number
of heroin users and addicts. It is estimated that currently
there are about 120,000 to 150,000 heroin users in Ger-
many. Up to the mid 1980s, the national drug policy in
Germany had been oriented towards the so called 'absti-
nence paradigm', but due to the rise of HIV-infections
among injecting drug users the developments in legal,
medical and political areas then changed towards a more
pragmatic and harm-reduction oriented strategy [1-5].
Although the first experimental methadone project had
already been carried out in Hanover in the mid 1970s,
substitution treatment for heroin users remained a con-
troversial issue in Germany for a very long time, because
the study's conclusions were misguided by the majority of
drug experts and politicians. Despite the fact that there
was a 100 % reduction in criminal activities as well as
social reintegration and vocational/occupational rehabili-
tation, the trial was deemed a failure because the patients
failed to achieve and maintain abstinence [6].
On a larger scale this treatment option was introduced rel-
atively late, primarily in response to the threat of the
increasing prevalence of HIV and AIDS among injecting
drug users (IDU) in Germany in the mid 1980s. However,
it reflected rising public nuisance associated with drug
use, increasing mortality rates among drug users, the lack
of attractiveness of abstinence-oriented services and
strong advocacy by a handful of dedicated parents of
addicts in collaboration with an equally small number of
GPs. These factors finally led to the implementation of
harm-reduction-oriented services, i.e. low-threshold
drop-in centres and syringe exchange schemes. The first
large-scale methadone maintenance treatment pro-
gramme (MMTP) was started in 1987 within the scope of
a model project in one federal state (North-Rhine West-
phalia). [7,8]
The German Narcotics Act was revised in 1992, finally
clarifying that substitution treatment for opioid depend-
ence is legal. Up to the present substitution treatment has
been the most important part of the options available for
the treatment of opioid dependence. Over the past 15
years the overall number of participants in drug-substitu-
tion treatment has risen from some 1,000 in the late
1980s to 65,000 in 2006 [9], and although MMT has been
evaluated comprehensively in Germany with favourable
outcomes there is still a lack of availability of, and acces-
sibility to, substitution treatment. [10]
Until the early 1990s methadone could only be adminis-
tered to drug users when highly specific indication criteria
were met (e.g. emergency cases, such as life-threatening
conditions of withdrawal, severe pain, pregnancy or HIV
infection). However, there were a few general practition-
ers (GPs) who ignored the legal regulations and pre-
scribed methadone to opiate addicts, but most of them
were persecuted and prosecuted. Some GPs started pre-
scribing codeine or dihydrocodeine (DHC) (provided in
the form of juice) as these substances were not restricted
by narcotic law [11]. Other doctors followed this example
and over many years codeine or DHC came to be pre-
scribed to very large numbers of addicts under a loop-hole
in narcotics regulations.
After several pilot programmes showed MMT to be effec-
tive the German Social Health Insurers (SHI) approved
this treatment modality and introduced, in 1991, metha-
done treatment guidelines for financing this kind of treat-
ment. In Germany treatment and prescription
(medication) costs are generally paid by public health
insurance schemes (SHI) that provide legally mandated
coverage for almost 90 percent of the population (in spe-
cial cases, e.g. homelessness, doctors' fees are met by
social welfare services). There is also the freedom to
choose one's own general practitioner (GP) or hospital.
Legal framework of substitution treatment
Since the 1920s, when the first Narcotics Act had been
introduced in Germany, the main emphasis of legislation
was placed on developing instruments for the control of
the narcotic drugs trade rather than on measures of pre-
vention, care, treatment and rehabilitation. Today, the
purpose of the Narcotics Act is, above all, to ensure that
there are sufficient supplies of licit narcotics for the medi-
cal care of the population (particularly for the treatment
of severe conditions of pain), and, in addition, to mini-
mize the likelihood of abuse of narcotic drugs and the
emergence and maintenance of addiction as far as possi-
ble. Since 1981 increasing numbers of drug addicts and
drug-dependent offenders led to an inclusion of detailed
provisions of activities to reduce the demand for narcotics
and to reduce drug-related harm, inter alia "therapy
instead of punishment" (1981), substitution-based treat-
ment and distribution of sterile disposable syringes
(1992) and medically supervised injection facilities (drug
consumption rooms) (2000).
Substitution treatment of opiate addicts involves the reg-
ular prescription and administration of opiates pursuant
to the Narcotics Act. However, the most important man-
date is, that in addition to making the required doses of a
substitute available, substitution treatment has to consist
of a comprehensive and qualified addiction therapy
including psychiatric, psychotherapeutic and/or psycho-
social measures of treatment and care. Therefore, a close
co-operation between physicians and other addiction spe-
cialists (e.g. psychiatrists, psychologists, psychosocialPage 2 of 13
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treatment plans have to be designed for each single
patient.
Doctors have to register their patients at the Federal Nar-
cotics Control Board (Bundesopiumstelle) to ensure there
is no evidence that a patient receives substitution sub-
stances on prescription from another doctor, fails to par-
ticipate in necessary accompanying treatment and care,
uses substances that endanger the purpose of substitution
treatment, or uses the substitute in a manner that is pro-
hibited by law (e.g. intravenous use).
Doctors are obliged to document all relevant patient and
treatment data. These include case/medical history and
results of (physical) examination; indication, diagnosis,
treatment goals; formulating of and working towards nec-
essary accompanying support and services (e.g. psychoso-
cial counseling); encoded and anonymous notification of
patients to the central substitution register; frequencies
and results of drug screenings and supervision of addi-
tional use of psychotropic substances; information on the
dangers and side effects of collateral substance (mis)use;
substitute substance, form, dosage, and dispensing
modalities; justification for take-home dosing and current
state of treatment; justification for exclusion from treat-
ment; and an individual treatment plan.
Every year, the regional SHIs check a small percentage of
documentations by randomly selecting GPs' offices. Sub-
stitute substances must not be prescribed for parenteral
(intravenous) use. The substitutes prescribed may be dis-
pensed and/or taken under supervision in GPs' offices,
hospitals, pharmacies or other facilities approved by the
relevant state authorities. Take home medication for up to
seven daily doses is possible when the determination of
the maintenance dose has been settled and when there is
no noxious and/or intravenous concomitant use of other
psychotropic substances. Regarding international travels
up to 30 take home doses are allowed to be prescribed
within a period of 12 months. There are no regulations
regarding the minimum age of the patients.
All doctors seeking to provide drug-substitution treatment
need special authorization issued by the relevant regional
medical boards, and they must provide evidence of having
participated in pharmacology and drug addiction training
programmes. Training courses are organised by the
regional medical boards and span 50 to 60 hours. They
cover topics such as opioid dependence and the role of
substitute medication, understanding and caring for the
substitution patients, assessment and management, and
other aspects of clinical practice [12].
Financing of substitution treatment
Until 2004 SHI funded patients and most patients sup-
ported by social welfare had to suffer from illnesses in
addition to drug addiction itself to be eligible for substitu-
tion treatment. Since then it is sufficient to be diagnosed
as being addicted to heroin. In general practice drug users
will be accepted for treatment when there is a docu-
mented history of compulsive opioid use of two years
(according to SHI) and when they are at least 18 years old.
Despite the fact that the SHI guidelines are effective
nationwide there are variations among the federal states
with respect to the organization and delivery of substitu-
tion treatment and accompanying psychosocial care.
Depending on the number of substitution treatment pro-
viders in a given area doctors can be authorized to treat up
to 20 patients or more funded by (SHI). There is no such
limitation specified in the Regulations on the Prescription
of Narcotics. Thus doctors approved to treat 20 SHI
patients may care, for example, for another 20 patients
funded by social welfare or an unlimited number of
patients who pay for treatment and medication on their
own.
Guidelines of the Federal Medical Board on substitution 
treatment – improvement of quality of substitution 
treatment
The guidelines of the German Medical Association on the
substitution treatment of opiate addicts, effective since
March 2002, specify that treatment is indicated in cases
where:
• a manifest opiate dependency is of long standing and
attempts at achieving abstinence have not been successful,
• substitution treatment offers the best chance of healing
or improvement when compared with other treatment
options.
The aim of substitution treatment is to stabilise the drug
addicts' health status and gradually move them towards
abstinence. It is essential that the accessibility and quality
of substitution treatment be further improved. Alongside
the implementation of the measures hitherto envisaged
for this purpose it is particularly important to:
• improve the psychosocial, psychiatric and psychothera-
peutic measures for providing treatment and care and to
offer them in sufficient quantities,
• set up quality circles on substitutive therapy at the
municipal level.
Substitution treatment is an essential pillar of the treat-
ment of opiate addicts in Germany. To improve qualityPage 3 of 13
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falen-Lippe launched a 'manual on outpatient substitu-
tion treatment of opioid addicts'. The manual describes
how to define quality and how to ensure that all everyday
measures and services are of high quality. The key meas-
ures discussed are medical and nursing activities (assess-
ment, diagnosis, documentation, provision of dosage,
supervision). This manual is widely used (by 1,000 GPs)
as a basis for ensuring good quality in substitution treat-
ment [13].
Provision of treatment and treatment goals
Various forms of treatment organizations have been
developed in Germany. Out-patient counseling services
offer contact, motivational and out-patient treatment,
whereas detoxification is generally carried out in so-called
"regular hospitals" or in a few specialized institutions. In
Germany, detoxification is generally carried out in in-
patient treatment settings, although there is evidence that
out-patient detoxification is also working. There are vari-
ous kinds of institutions caring for opioid addicts during
the phase of rehabilitation, e.g. specialized units at hospi-
tals, specialized clinics or therapeutic communities. In the
course of further treatment and after care a wide range of
assistance is offered depending on the addicts' needs (con-
cerning, for instance, job finding, housing projects or life
in communities). Experts who have generally qualified in
specific further education work in these special fields. [14]
The aim of all these offers is to stabilize health and, in the
long run, abstinence from drugs. Substitution is the only
field which offers non-drug-free treatment. However, sub-
stitution is a method which reaches remarkably more
drug addicts than any other approach of addiction treat-
ment. So far the linking of the regular system of health
provided in Germany and the special addiction treatment
system to an efficient unity has not been completely satis-
fying though co-operation and co-ordination at a regional
level are partially well developed.
One of the main standards in drug addiction treatment is
the co-operation of different professions including social
work/education, psychology and medicine. Operators of
centres, the Federal Laender or municipalities, are respon-
sible for quality management and professional supervi-
sion of out-patient services.
In contrast to a strong abstinence orientation in the early
1990s the treatment goals are now realistic and pragmatic,
such as:
• to assist the patients to stay healthy until, with the
appropriate care and support, they can achieve a life free
of drugs
• to reduce the use of illicit and non-prescribed drugs by
the individual
• to deal with the problems related to drug use
• to reduce the dangers associated with drug use, particu-
larly the risk of death by overdose and HIV and hepatitis
infections from injecting and sharing injecting parapher-
nalia
• to reduce the duration of episodes of drug use
• to reduce the chances of future relapse to drug use
• to reduce the need for criminal activities in order to
finance drug use
• to improve overall personal, social and family function-
ing
Addicts seeking to cope with their addiction with profes-
sional support are offered a wide range of assistance
approaches to step out of drug use, and there are many
therapeutic services available.
Even persons participating in substitution treatment can
occasionally be motivated to move on to abstinence ther-
apy. Therefore, a strong co-operation between non-insti-
tution doctors and inpatient as well as outpatient addict-
support services is necessary to facilitate steps towards
abstention from drugs. Furthermore, inpatient drug-ther-
apy facilities must provide slots offering a substitution
introductory phase with subsequent abstinence treat-
ment.
Meanwhile, first specialised clinics have been established
which also admit clients who are on substitution treat-
ment with the aim of achieving and stabilising abstinence
in the course of treatment. Preliminary results show that
the success rates of such clinics do not lag behind those
achieved by abstinence-oriented therapy. [15]
Expanding services to improve occupational integration
Regarding employment, the labour market is not easy to
access for patients participating in drug-substitution treat-
ment, due to a high general unemployment rate in Ger-
many (10.8% in March 2006 = nearly 4.8 million jobless
people) and negative attitudes and beliefs towards the
patients on the part of employers. Also, the socio-demo-
graphic and biographical characteristics of patients in sub-
stitution treatment (e.g. minor school and vocational
qualifications, criminal records) reduce the chances of get-
ting employed. Though there are educational and voca-
tional projects in several major cities accompanyingPage 4 of 13
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sufficiently available.
Unemployment is associated with processes of impover-
ishment, resulting in a large number of psychosocial risks
which can have a reinforcing effect on drug use and on the
development of substance-related addiction. This is why
the German government and treatment services lay great
store by the integration into society of persons addicted to
psychotropic substances through work and gainful
employment. Binding agreements and governing co-oper-
ation in the rehabilitation phase are critical between the
organisations providing medical and occupational reha-
bilitation. A great deal of development work awaits the
addict support services in this area in the future.
Additional work structures which have to reflect the differ-
ent capabilities and resources of patients are still missing.
Some patients have never functioned in traditional work-
ing settings and have to learn to follow certain demands
and structures from the very beginning. Others do already
have work experiences but are no longer familiar with the
demands of the working environment. Work for a certain
amount of hours in a charitable institution may constitute
one way to solve the problem for a few patients, but many
more options are needed to fill the free time and to be
effective. [16]
Promotion and qualification of self-help activities
Self-help groups (including parental self-help groups)
should be included to a greater degree in the co-ordinat-
ing and planning activities surrounding measures to
reduce the problems which arise in dealing with psycho-
active substances. They are an indispensable component
of the support offered persons who are at risk of addiction
or already addicted.
A landmark in the development of self-help activities has
been the growing of self-organisation of people who are
affected both by drug use and HIV. The opening up of the
health sector for self-help and the recognition of the com-
petence of those affected, thanks to the AIDS-Help move-
ment, has led to a new orientation of the somatically
focussed medical system in Germany, or at least to first
steps in this direction. The self-organisation of people
affected in the area of drugs via the development of JES-
groups (Junkies, Exusers, Substitute Drug Users) is the
most incisive challenge for drug policy and service provid-
ers. It requires discussion with the people affected and not
about them. In the meantime, JES groups in nearly 25 cit-
ies, with at least some 300 drug users in MMT actively
involved, are working as advocates for their own interests.
In their founding statement this philosophy is expressed
as follows: "JES is a federation based on solidarity among
junkies, ex-junkies and substitute drug users who express
themselves with the competence of those directly affected,
and demands recognition of their existence by state health
and drugs policies. Drug users have just as much right to
human dignity as everybody else. They do not have to
earn this right by abstinence or by conforming. They have
a right to humane, healthy and social living conditions."
[17]
Impact of MMT in Germany
Effectiveness of MMT has been proven
Worldwide, including Germany, methadone mainte-
nance treatment has been evaluated comprehensively [18-
21]. On account of different methodological approaches,
different evaluation periods and different sample sizes
and populations, the German research results are only
partially comparable. However, several important com-
mon aspects regarding the overall results of German stud-
ies and investigations can be presented [4]):
• The average age of methadone patients is above 30 years.
The duration of heroin use before starting MMT lies
between 10 to 12 years on average.
• More than two thirds of the patients had received treat-
ment in inpatient, drug-free therapeutic communities
(TCs) – usually several attempts at treatment – prior to
MMT but could seldom complete treatment as expected.
One third of the few who left regular therapy immediately
relapsed into heroin use.
• MMT shows considerably higher retention rates than
TCs (some 65% of clients leave TCs within the first four
months of treatment). In North Rhine-Westphalia, for
example, the retention rates were 87% after one year, 66%
after three years, 53% after five years and 48% after seven
years [8]. An evaluation of MMT in Hamburg showed
retention rates of 84 % after three years, 77 % after four
years, and 71 % after five years [21].
• Even during the initial phase of treatment there is a
remarkable improvement in the general health status of
methadone patients. The health status of patients infected
with HIV or hepatitis also stabilises in the course of treat-
ment. HIV seroconversion rates are well below 1% per
year during MMT.
• The risk of mortality is drastically reduced. The survival
rate of methadone patients is three to five times higher
than of untreated heroin users.
• There is also a reduction in the use of illegal drugs. The
decline in illegal use of opioids comes about in a linear
way; final cessation is dependent on the duration of par-
ticipation in treatment. After one year in MMT positive
heroin urinalysis ceases among 80 to 90 % of methadonePage 5 of 13
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is also a decline in, or termination of, the additional use
of other psychotropic substances. (Additional use of other
psychoactive substances is not a reason per se to terminate
treatment but to change the treatment regime and to
determine reasons for this additional use)
• About 10% of treatment participants become totally
abstinent (including methadone) [22]. At present, there
are no follow-up studies available on the stability of absti-
nence. However, experiences so far clearly indicate that
methadone treatment (detoxification or maintenance-to-
abstinence) which is limited in time usually results in a
relapse into illegal opioid use and physical as well as psy-
chological instability [23].
MMT is the best investigated and most effective evidence-
based treatment of opioid dependents: "Given the
chronic, relapsing nature of opioid dependence and the
generally disappointing long-term results of detoxifica-
tion in combination with relapse prevention, agonist
maintenance treatment has become the most important
treatment modality for opioid dependence" [24].
Taking account of the results of the pilot programme on 
heroin-supported treatment in the further development of 
addict support systems
Although the implementation of MMT has had very posi-
tive results in Germany, a certain percentage of partici-
pants do not benefit from his type of treatment. This
opened the discussion for a diversification of MMT, espe-
cially for refractory opioid dependent subjects (either hav-
ing dropped out of MMT or non-responders in MMT). The
positive results of the Swiss heroin trial paved the way for
a randomised clinical trial in Germany. [25]
The results of the scientific evaluation of the German pilot
project on the heroin-supported treatment of opiate
addicts had been recently evaluated [26]. The findings are
to be incorporated into the treatment provided to persons
suffering from serious heroin addiction who are failing or
who have failed to respond well to MMT. Only those opi-
oid addicts were included for whom methadone mainte-
nance had proven ineffective (often during multiple
enrolments) or who had not been in treatment for at least
6 months before being included in the heroin trial.
The study was conducted in 7 German cities and 1,032
patients were included at the study centres from 2003 –
2005. One study group was provided with diamorphine
(heroin), the other group with methadone. In addition,
both groups received special psycho-social support. The
retention rate regarding heroin treatment was 67 % after
12 months, slightly lower than the rates reported in stud-
ies in Switzerland and the Netherlands. Of the methadone
group, only 39 % completed the study treatment. This is
mainly a result of the failure of one third of the ran-
domised patients of the control group to show up and
start treatment. It must be considered, however, that, at
the 12-month examination, 39 % of the dropouts of the
heroin group and 44 % of the dropouts of the methadone
group were either still in maintenance treatment outside
the study conditions or in other addiction treatment set-
tings.
What are the main results of the study? The group of
severely ill heroin addicts was successfully recruited. The
response-definition was an improvement by 20% in
health, a considerable decrease in street heroin consump-
tion and no increase in cocaine use. After 12 months her-
oin treatment showed significantly better results with
respect to improvement in health and the reduction of
illicit drug use than methadone treatment. The effects
were largely independent of the target group, psychosocial
intervention forms and study centre. There was a reduc-
tion of cocaine use in both groups. The study demon-
strates that heroin treatment can be safely and effectively
implemented. No study-related death was reported. The
mortality rate was equal in both groups, all death cases
were due to previous illnesses. However, higher safety
risks in the heroin group (because of injection of the sub-
stance) call for treatment in special out-patient clinics and
seem to preclude take home medication. Heroin treat-
ment was significantly better than methadone treatment
to the group of long term drug users who had previously
failed to obtain much benefit from MMT and other forms
of treatment with respect to improvement in health and
decrease of illicit drug use. As an important additional
value, heroin prescription led to a considerable reduction
in drug related crimes.
Psychosocial support – patients' expectations and 
experiences
The regulations of substitution treatment in Germany
demand mandatory participation of patients in psychoso-
cial care, although there is no empirical evidence of a gen-
eral necessity of psychosocial support for all patients [27].
However, these regulations do not provide any instruc-
tions on the frequency, mode and scope of psychosocial
care provisions and, to date, there are no nationwide
standards on how to organize and structure accompany-
ing support. Psychosocial care is a collective name for a
number of different services. These may include, for exam-
ple, legal advice, managing financial problems (e.g. debts,
rents), recreational activities, crisis intervention, (psycho-
therapeutic) group sessions, assistance with finding
accommodation and jobs, and qualifying for school and
vocational training. Psychosocial care is not funded by the
SHI. There are great variations in psychosocial provisionPage 6 of 13
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in quality and funding.
Special cognitive-behavioural interventions might help to
reduce additional consumption of psychoactive sub-
stances [28]. An alternative strategy is contingency man-
agement (CM), in the scope of which patients are given
positive reinforcement (e.g. vouchers or take-home dose)
for each drug-free urine. A multi-centre randomized trial
is under way [29].
Worldwide, there is a lack of qualitative research on the
subjective views of patients participating in substitution
treatment. The attitudes and views of treatment partici-
pants deserve to be studied carefully, because one may
assume that the more treatment philosophies, policies
and settings are oriented towards patients' needs the more
favourable outcomes might be expected. [30,4] There is
clear evidence of this from reports of patients: "The doctors,
they only know about the effects and side effects from book, but
we are the experts. For instance, the doctor says, that everyone
who gets methadone feels the same thing but that's not true."
[31].
Psychosocial counseling can support patients with struc-
turing their life again, based on changed values, because
the pressure to find drugs is reduced substantially. How-
ever, often there are massive problems revealed which
might lead to a state of crisis, because the confrontation
with injuries, illnesses and other negative experiences of
their past can be very painful. The loss of daily structures
(and generally all-consuming) activities focused on
financing and consuming drugs, the loss of the euphoric
effects of substances like heroin and the consequences of
massive illness (dual diagnosis, viral infections) and lim-
ited future prospects might often lead to depression. Some
patients become apathetic and unable to structure their
lives. They, for example, hang around all day long watch-
ing TV.
Former social networks no longer have the same function
they once had. Keeping a distance from the 'drug scene'
and establishing a new life is not easy when meeting 'old
acquaintances' at the substitution doctor's office every
day. The additional use of alcohol and benzodiazepines
might function as a kind of self medication to deal with
depression but often has the opposite effect. [32]
Improving family life is not easy without professional
support, because family integration plays an ambivalent
role. Early childhood family experiences are often 'part of
the problem'. Family involvement is crucial for the suc-
cessful treatment while its dynamics might only be under-
stood and confronted with expert psychological support.
Provision of substitution treatment
It is estimated that about 90% of substitution patients in
Germany receive their medication from doctors in inde-
pendent medical practice (GPs), i.e. not in clinics. How-
ever, these practices are mostly run by specialised teams
and the patients are nearly exclusively drug addicts. In a
survey from spring 1996 in a West-German region 70% of
all SHI approved methadone prescribers (598 physicians)
in the area were general practitioners, 20% specialists in
internal medicine and 6% psychiatrists [33]. About 50 %
of GPs in MMT have up to 10 patients, 40 % up to 40
patients and 10 % more than 40 patients. 78 % of the
61,000 patients registered in 2005 got treatment in spe-
cialised out-patient services (with their own psycho-social
staff), 20 % in practices which were also treating other
patient groups, but offering special services for drug users,
and (only) 4 % in 'normal' practices of family doctors.
[34].
Endorsed by the umbrella organization of the German
Association of Pharmacists substitute substances may be
legally dispensed via pharmacies since 1998. Table 1
shows the number of registered patients in substitution
treatment in Germany.
Substances prescribed
When substitution treatment started in Germany only lev-
omethadone was used as a "substitute" (surrogate sub-
stance). Now also methadone, buprenorphine and in
particular exceptional cases codeine or dihydrocodeine
may be prescribed. LAAM or levacetylmethadol (Orlaam®)
is no longer used in Germany because of dangerous side
effects (life-threatening cardiac disorders) [35,36].
Methadone is the substance most frequently prescribed in
substitution treatment. In contrast to other countries,
there are two forms of methadone available in Germany,
the racemic mixture (d, l-methadone) (only available
since February 1, 1994) and levomethadone (l-metha-
done, L-Polamidon®). Apart from MMT methadone is also
used during detoxification in approved detoxification
units where the doses are gradually reduced over a period
of one to three weeks.
Regarding codeine/DHC a follow-up study showed that
MMT and codeine/DHC treatment are similarly effective
in treatment progress and outcome [37,38]. Nevertheless,
codeine no longer plays a role in substitution treatment.
Due to a change of law – because of severe problems
raised by wide medically uncontrolled spread of 'codeine-
juice' – the number of codeine/DHC patients decreased
from some 25,000 to 30,000 patients in early 1998 to
some 5,000 patients in 2001 and to less than 500 in 2005.Page 7 of 13
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was approved for substitution treatment by the Federal
Institute for Drugs and Medical Devices (Bundesinstitut
für Arzneimittel und Medizinprodukte) in early 2000 –
has been provided with increasing frequency. It has been
suggested that buprenorphine might be especially useful
with pregnant women and low-dosed methadone patients
[39]. Buprenorphine also appears to be effective when
used in detoxification treatment [40]. A report recently
published by a Hamburg clinic on the experiences made
with the use of buprenorphine (31% of the cases) in com-
parison with methadone (69%) in withdrawal treatment
suggests indications for both substances. The study was
carried out on 800 patients between 2000 and 2004. All
in all, no significant difference was found for the retention
rate (methadone: 52%; buprenorphine: 59%). During
methadone withdrawal treatment, 8 out of 10 patients
who had undergone long-term methadone substitution
displayed significantly less withdrawal symptoms under
buprenorphine. The use of buprenorphine in addicted
pregnant patients resulted in considerably reduced or
absent neonatal withdrawal symptoms. Treated with
buprenorphine instead of methadone the patients
reported a clearer and more conscious state of mind which
was not experienced as positive by all patients, and psy-
chiatric co-morbidity may have been negatively influ-
enced. As a result of careful approach, especially when
changing the substances, there were no cases of overdose
emergencies during the period under review [41]. Several
studies have shown buprenorphine to be effective in
maintenance treatment of opioid dependence [23,42].
However, there are no comparative studies on post-
detoxification relapse rates. Table 2 shows the substances
used for substitution treatment in Germany.
In a study from Austria [43] patients receiving slow-
release morphine in substitution treatment reported
lower rates of additional heroin (22.4 % vs. 35.1 %),
cocaine (40,9 % vs. 58.3) and benzodiazepine use (74.1
% vs. 88.9 %) compared to those patients who got meth-
adone. The findings confirm other studies indicating that
slow-release morphine might offer an alternative in sub-
stitution treatment highly appreciated by patients. To
date, however, this substance is not available for substitu-
tion treatment in Germany.
A 'gold standard' in substitution treatment should not be
concentrated on a certain substance, but on the imple-
mentation of the individually used substance into a treat-
ment setting which is based on patient's needs, clear
regulations, balanced goals and a good patient-doctor
relationship [44].
Substitution treatment in prisons
Under German law the consumption of narcotic drugs as
such is not defined as a criminal offence. However, any-
one who possesses narcotic drugs for private use and does
not have a written permission for their acquisition, is con-
sidered to commit an offence pursuant to the Narcotics
Act (so-called personal consumption offence), just as any-
one who cultivates, produces and trades with narcotics or
otherwise brings them into traffic without any official
authorization. For this reason a considerable number of
opioid addicts in Germany have experienced prison sen-
tences.
In Germany there are approximately 80.000 prisoners, of
whom 25 % are considered to be 'problematic drug users'.
Up to 50 % of inmates have experienced the use of illicit
drugs (mostly cannabis). According to the German Prison
Act, each of the 16 federal states is independently respon-
sible for providing adequate medical care to prisoners.
Medical care must comply with the medical standards
applied outside the prison system. A great number of
inmates have a history of injecting drug use and a certain
percentage of whom is, although less frequently, still con-
tinuing injecting opioids while in prison. Despite rigid
controls, it is estimated that 50 % of imprisoned intrave-
nous drug users continue drug taking while in prison [45].
This is associated with high risks of HIV and hepatitis
infection transmitted by sharing injecting equipment:
sterile syringes and needles are rarely available in prisons.
Given these facts there is clearly an opportunity to imple-
ment preventive measures within the prison system. Drug
treatment can be effective if it is based on sufficient length
and quality and continuing aftercare. Meanwhile, in
accordance with the WHO "Guidelines of HIV and AIDS
in Prisons (WHO, 1993) [46], which recommend that
"prisoners on methadone maintenance prior to imprison-
ment should be able to continue this treatment while in
















From 1992–2000 estimations and data from Health Insurances and 
Medical Associations; from 2002–2006 data from the federal registry. 
No data were available for 2001.Page 8 of 13
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Germany. However, the implementation is the responsi-
bility of each of the 16 federal states (Laender) and even
varies from prison to prison. There are several important
distinctions from the services outside the prison system
[47,48]. Inmates as patients have no right to choose their
doctors; it is not possible to dissociate the patients from
the specific intramural inmate 'drug scene', and often
there is a lack of positive attitude of the staff towards sub-
stitution treatment. Only 6 out of 16 federal states provide
substitution treatment in prisons. It is estimated that not
more than 700 inmates participate in substitution treat-
ment whereas at least 1/3 of the 10.000 intravenous drug
users in prisons on an average day should be eligible for
substitution treatment. Admission criteria vary between
the states and long-term maintenance treatment is often
not an option. Substitution treatment is generally an inte-
gral component of a broader drug service concept to reach
and stabilise abstinence, to improve access to further treat-
ment after release and to improve relapse prevention. Psy-
cho-social care is provided by social workers from outside
the prison, but due to lack of financial resources often falls
on prison staff. Sometimes self-help groups (AIDS self-
help groups or drug user groups) from outside the prison
are allowed to support inmates in treatment. Prison sys-
tems are found to be slow in response to epidemics of
viral infectious diseases and injecting drug use. However,
substitution treatment is known to be an effective
response in minimizing the risks and harms of opioid
dependent prisoners by reducing heroin use, drug inject-
ing and needle sharing, and prison based drug-trade. The
provision should be broadened [49].
Role of substitution treatment in the treatment of HIV and 
hepatitis among drug users
Drug users are the second largest risk group of people liv-
ing with HIV-infections in Germany (the largest group are
homosexual men), whereas the group of heterosexual
contacts and of people from high-risk countries is quite as
large as the drug users' group). According to the Robert-
Koch-Institute [50], HIV incidence is at 5.8% (2003:7.0%)
among the group of IDU. Until 2000, the figure was 10%
and in the mid 1980's there was an incidence rate of 20 %.
In some greater cities the percentage of HIV-diagnoses
among IDU was about 50 – 60 %. This percentage has
dropped significantly due to the implantation of low
threshold facilities and MMT. Data from outpatient coun-
seling services show a prevalence of 3.7%. However, it
must be noted that recent, large-scale studies allowing for
a certain generalization of data are missing.
In summary it may be concluded that intravenous con-
sumption was the probable cause of infection in less than
10% of the new cases and that, in general, less than 5% of
the IDU were HIV-positive in the year 2004.
Basic data on viral hepatitis are available for the general
population. According to the Federal Health Report [51]
5–8% of the German population in the age of 18–79 years
were affected by a hepatitis-B-infection. A total of 0.5–
0.7% of the population carries hepatitis-C-antibodies. As
for possible ways of transmission, intravenous drug use
was mentioned by 7 % among the hepatitis-B cases. In
respect to hepatitis-C cases, intravenous drug use at any
time in the past was most frequently reported – by 37% of
the cases – as the likely route of transmission. In the group
of the 20 to 29 year-old male cases, intravenous drug use
was reported by 71%. A vaccination study carried out in
the open drug scene took a sample of 701 persons finding
an antibody prevalence of 38.6% for hepatitis A (anti-
HAV), 2.1% for hepatitis B (HBs-Ag) and 34.1% (anti-
HBc) as well as 47.5% for hepatitis C (anti-HCV). Only
one in five had known they where infected [52]. A survey
carried out among 1,512 opiate addicted patients partici-
pating in qualified treatment in a Munich clinic, showed
the following results (portion of men: 85%, average age
27.7 years, duration of heroin use: 7.8 years, IDU for 6.7
years): hepatitis A was found in 57.7% of the patients,
HBV in 33.0% and HCV in 75%. A positive result for HBV
and HCV correlated positively with age, duration of intra-
venous consumption and number of withdrawal treat-
ments respectively [53].
Summarizing, the antibody prevalence (infection rate) of
hepatitis B among IDU in Germany can be estimated to
range between 40–60% and for hepatitis C between 60–
80%. While the data do not permit precise estimates, it is
quite obvious that the antibody prevalence in IDU is very
high regarding hepatitis B and C.
MMT is the major basis for the treatment of HIV/AIDS-
related illnesses among drug users. High retention rates
and good compliance with treatment instructions facili-
tate treatment with antiretroviral medications, either pro-
vided in specialised out-patient MMT programmes or in
close cooperation with specialised HIV/AIDS hospital
units [54]. Long-term substitution programmes allow
observation of the course of antiretroviral treatment and a
Table 2: Substances used for substitution treatment in Germany
Substances for substitution 2002 2003 2004 2005
Methadone 72,1 % 70,8 % 68,3 % 66,2 %
Levomethadone 16,2 % 14,8 % 15,0 % 15,8 %
Buprenorphine 9,7 % 13,0 % 15,6 % 17,2 %
Dihydrocodeine 1,7 % 1,2 % 0,9 % 0,7 %
Codeine 0,3 % 0,2 % 0,2 % 0,1 %
Die Drogenbeauftragte der Bundesregierung: Drogen- und 
Suchtbericht 2006 (Federal Drug Commissioner: Drugs and Addiction 
Report 2006), Berlin, p.69Page 9 of 13
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tial drug interactions between antiretroviral medications
and methadone and other substitute substances. Adapta-
tions of methadone dosages may be necessary. The anal-
gesic properties of opioids may mask early symptoms of
serious side effects of HIV medications. A good relation-
ship between doctor and patient is essential to deal with
these problems. In a retrospective study of antiretroviral
treatment of drug users (A) and homosexual men (B) in
an outpatient specialised centre in Berlin, drug users
showed a higher psychiatric co-morbidity, but overall
results were similar. After 12 months in treatment the HI-
virusload of 44 % of group A was below the limit of detec-
tion, compared to 51 % in group B. However, the mortal-
ity rate in the drug user group was significantly higher
because of deaths due to heart (endocarditis) or liver fail-
ure (hepatitis) [55]. Nevertheless, compliance and adher-
ence to ARV (Antiretroviral Therapy) or HAART (Highly
Active Antiretroviral Therapy) depend on numerous fac-
tors, such as good patient-doctor-relationship, prevalence
of psychiatric disorders, level of patients' self-esteem etc.
While in the past IDU had usually been excluded from
standard HCV-therapy with Interferon and Ribavirin in
Germany, most recent results suggest a different approach.
[56,57] Comparisons were made regarding the use of
medication in drug users and non-drug users on the basis
of the following criteria: response rate, outcome of the
HCV-standard therapy as well as severity of neuropsycho-
logical side-effects.
• In a controlled prospective study from 2003 [58] no dif-
ferences were found in persons displaying an addiction
related or psychological disorder and a control group
without such disorders with regard to psychiatric compli-
cations and response rates. However, drug users had a
higher drop-out experience.
• In a controlled prospective study from 2004 [59] the
treatment outcome of 50 patients in methadone substitu-
tion treatment was compared with that of a control group
of persons without addiction problems over a period of 5
years. No significant differences were found between the
groups, neither for the retention rate nor for the response
rate.
• In a group of 40 heroin addicts suffering from severe
additional symptoms, [60] response rates were found to
be similar to those of the general population.
The results of these studies and other surveys [61,62] sug-
gest that HCV-infected IDU may be successfully treated
with a standard therapy. Side effects and response rates
correspond with the figures found for the general popula-
tion. Simultaneous substitution treatment is not an obsta-
cle, but management of both therapies should be closely
coordinated [63]. Even in the case of light or moderate
additional psychological disorders, HCV-treatment may
be carried out successfully, provided it is organized on an
interdisciplinary level. [64]. In general, MMT is a prereq-
uisite for a successful additional treatment of HIV or hep-
atitis in opiate addicted individuals. [65]
Discussion
After a long and controversial debate methadone mainte-
nance treatment (MMT) was only introduced in Germany
in 1987. The number of patients in MMT was low at the
beginning because of strict admission criteria, but it has
been constantly rising since the 1990s reaching 65,000 at
the end of 2006.
One important objective of health policy is to do the
utmost to prevent or at least considerably reduce in our
society risky and damaging using patterns as well as
dependence on addictive substances. Addiction preven-
tion therefore occupies a prominent place in policy
efforts. However, it is also an objective to be able to recog-
nize risky consumption patterns at an early stage and
reduce them, ensure the survival of those affected and
treat cases of dependence with all of the possibilities avail-
able according to the current level of scientific knowledge
– from abstinence to medically supported therapy. Addic-
tion is a disease that requires treatment.
In Germany, addicts have a legal right to be offered assist-
ance. The bodies responsible for providing social security
benefits (the health insurance funds, pension insurance
funds, institutions responsible for social assistance, the
municipalities) are obliged to finance such assistance.
Together with the service-providers and self-help groups,
they have succeeded over the past decades in making
available a differentiated range of addiction and drug
assistance services and facilities which provide addicts in
need assistance with a broad spectrum of different sup-
port. Over the past 30 years, a high-quality and differenti-
ated treatment system has been developed in Germany in
the area of assistance to addicts. This system comprises
outreach and low-threshold forms of assistance, outpa-
tient counseling and treatment offers, qualified with-
drawal treatment, inpatient detoxification treatment with
a subsequent adaptation phase and follow-up, post-inpa-
tient care within the framework of integration (for exam-
ple: outpatient rehabilitation, special care housing,
occupational rehabilitation projects, follow-up care and
self-help groups). These offers are supplemented by a
medication-assisted outpatient treatment system espe-
cially designed for opiate addicts. Co-operation between
non-institution doctors and the addict-support system is
to be promoted at the interface with acute medicine.Page 10 of 13
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which treatment is best for an individual patient or even
for broadly defined subgroups of the addict population)
constitutes a key research question [66].
Nevertheless, substitution treatment plays a substantial
part in the health care system provided to drug users in
Germany.
Conclusion
In Germany, a history of substitution treatment spanning
20 years has meanwhile accumulated a wealth of experi-
ence, e.g. in the development of health care services
research; in the development of guidelines and the imple-
mentation of quality assurance measures; in the practical
implementation of substitution treatment with concomi-
tant effects and treatment elements such as drug-taking
history, dosage setting, co-use of other psychoactive sub-
stances (alcohol, benzodiazepines, cocaine), manage-
ment of 'difficult patient populations', integration of the
social environment; in the development of programmes
designed for psychosocial therapies adjuvant to substitu-
tion treatment and, in the framework of the pilot project
of 'heroin-based treatment', also with standardised manu-
als; in allocation research, to find the 'right' therapy form
at the 'right' point in time [66]; in the pilot project 'her-
oin-based treatment' through experience with patients
who do not benefit from methadone treatment; through
expertise in the treatment of specific co-morbidity such as
HIV/AIDS and hepatitis and psychiatric co-morbidity; in
the (Europe-wide) use of substitution treatment in pris-
ons; in the promotion and involvement of self-help
groups that are highly relevant; in the production, licens-
ing, distribution and control of substitution agents
including the setting up of a substitution register; in the
framework of the programme 'entwicklungsorientierte
Drogenkontrolle' (development-oriented drug control) of
the gtz, the German Agency for Technical Cooperation, in
the establishment of alternative development co-opera-
tion; in the framework of co-operation with the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA), in the development of Europe-wide stand-
ards for substitution treatment.
By combining preventive, therapeutic and repressive
measures, drug use should be avoided as far as possible,
or, respectively, its consequences should be minimized.
To improve the efficiency of public funding for treatment,
the co-operation between drug field and standard systems
of public help (e.g. youth-oriented help, help for unem-
ployed people) further needs to be developed. Quality
assurance of treatment is an important tool of improve-
ment of treatment results. Substitution treatment has
become a necessary and the most important part in the
treatment process in Germany.
Substitution treatment is widely used, not only in Ger-
many, but in total Europe. After the late 1980s, the rate of
MMT accelerated. By 2001, 24 EU countries as well as Bul-
garia, Romania and Norway had introduced MMT. Since
the mid-1990s also buprenorphine has become a strong
part of substitution treatment in Europe [67]. It is esti-
mated that nearly 600.000, more than half of the esti-
mated one million opioid users in Europe, have access to
substitution treatment.
But the highest dynamic in the future might be developed
in Asia and Eastern Europe. More than half of the world's
opiate users are living in Asia and even if the number of
drug users per capita is lower than in Europe, the absolute
numbers of opioid dependents has been rising dramati-
cally over the past 10 years. It is estimated that currently
there are more than 3 m heroin users in China (1.4 m are
officially registered), 2 to 4 m opioid users in the Islamic
Republic of Iran, several hundred thousand in India and
Pakistan, more than 170.000 in Vietnam, several hundred
thousand in the Central Asian region, 3 m in the Russian
Federation and 380.000 in Ukraine [68]. In nearly all of
these countries, apart from Russia which is still rejecting
substitution treatment, new substitution treatment pro-
grammes mostly providing methadone have been estab-
lished or are on the way. In the framework of the WHO
Collaborative Study on Substitution Therapy of Opioid
Dependence and HIV/AIDS in developing countries in
Asia and transition countries in Europe [69], convincing
results of methadone maintenance treatment had been
presented: both the health status and quality of life of the
patients participating improved significantly; the severity
of dependence clearly decreased by over 50%; also, there
was a strong decline in the development of depression;
neither HIV nor hepatitis C rates increased. Moreover,
high-risk consumption patterns, such as injecting, were
reduced significantly. Retention rates were very high after
six months, even if the average methadone dose was lower
in Asian countries than in Europe. MMT has been shown
an effective method for reducing illicit opiate consump-
tion. A rapid expansion of MMT programmes can be
expected in the next years.
Future cooperation with European countries, including
Germany, will be in demand, not only because of the pos-
itive experiences but also to prevent mistakes and failures.
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